09:24 AM EDT, 06/05/2025 (MT Newswires) -- Maia Biotechnology ( MAIA ) said Thursday that latest data from a phase 2 trial showed that treatment with its lead clinical candidate, ateganosine, extended median overall survival for patients with advanced non-small cell lung cancer.

The company said data showed a median overall survival of 17.8 months for the 22 patients who received at least one dose of ateganosine, about triple the overall survival of five to six months shown in studies of standard-of-care chemotherapy treatments for the disease in a similar setting.

The company added that the treatment has been generally well-tolerated so far.

Maia shares rose more than 5% in premarket activity Thursday.

Price: 1.85, Change: +0.09, Percent Change: +5.11